MA46464A - Polymorphes de l'agoniste de récepteur muscarinique - Google Patents

Polymorphes de l'agoniste de récepteur muscarinique

Info

Publication number: MA46464A
Authority: MA; Morocco
Prior art keywords: polymorphs; receptor agonist; muscarin receptor; muscarin; agonist
Prior art date: 2016-10-05

Application number

MA046464A

Other languages

English (en)

Other versions

MA46464B1 (fr

Inventor

Nira Bar-Ner

Abraham Fisher

Manfred Windisch

Original Assignee

Nsc Therapeutics Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-05

Filing date

2017-10-05

Publication date

2021-05-26

2017-10-05 Application filed by Nsc Therapeutics Gmbh filed Critical Nsc Therapeutics Gmbh

2021-05-26 Publication of MA46464A publication Critical patent/MA46464A/fr

2022-10-31 Publication of MA46464B1 publication Critical patent/MA46464B1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Toxicology (AREA)
Addiction (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)

MA46464A 2016-10-05 2017-10-05 Polymorphes de l'agoniste de récepteur muscarinique MA46464B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16192494		2016-10-05
PCT/EP2017/075373 WO2018065529A1 (fr)	2016-10-05	2017-10-05	Polymorphes cristallins d'un agoniste du récepteur muscarinique de l'acétylcholine

Publications (2)

Publication Number	Publication Date
MA46464A true MA46464A (fr)	2021-05-26
MA46464B1 MA46464B1 (fr)	2022-10-31

Family

ID=57083221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA46464A MA46464B1 (fr)	2016-10-05	2017-10-05	Polymorphes de l'agoniste de récepteur muscarinique

Country Status (30)

Country	Link
US (3)	US11008342B2 (fr)
EP (1)	EP3523310B1 (fr)
JP (3)	JP7163280B2 (fr)
KR (1)	KR102710640B1 (fr)
CN (1)	CN109790180A (fr)
AU (1)	AU2017341088B2 (fr)
CA (1)	CA3036134A1 (fr)
CL (1)	CL2019000532A1 (fr)
CO (1)	CO2019003003A2 (fr)
CY (1)	CY1125464T1 (fr)
DK (1)	DK3523310T3 (fr)
EA (1)	EA201990376A1 (fr)
ES (1)	ES2924432T3 (fr)
HR (1)	HRP20220962T1 (fr)
HU (1)	HUE059720T2 (fr)
IL (2)	IL265747B2 (fr)
LT (1)	LT3523310T (fr)
MA (1)	MA46464B1 (fr)
MD (1)	MD3523310T2 (fr)
MX (1)	MX383581B (fr)
PE (2)	PE20191003A1 (fr)
PH (1)	PH12019550048B1 (fr)
PL (1)	PL3523310T3 (fr)
PT (1)	PT3523310T (fr)
RS (1)	RS63438B1 (fr)
SG (1)	SG11201901612TA (fr)
SI (1)	SI3523310T1 (fr)
SM (1)	SMT202200331T1 (fr)
WO (1)	WO2018065529A1 (fr)
ZA (1)	ZA201901695B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20220962T1 (hr)	2016-10-05	2022-10-28	Nsc Therapeutics Gmbh	Kristalni polimorfi agonista muskarinskog acetilkolinskog receptora
US12201619B2 (en)	2018-03-22	2025-01-21	Nsc Therapeutics Gmbh	Compounds and methods for use in the treatment of microglia-mediated disorders
AU2021376267A1 (en) *	2020-11-03	2023-06-15	Cassava Sciences, Inc.	Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4855290A (en)	1985-05-10	1989-08-08	State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research	Derivatives of quinuclidine
US5534520A (en) *	1990-04-10	1996-07-09	Fisher; Abraham	Spiro compounds containing five-membered rings
US6797558B2 (en)	2001-04-24	2004-09-28	Micron Technology, Inc.	Methods of forming a capacitor with substantially selective deposite of polysilicon on a substantially crystalline capacitor dielectric layer
CA2450167A1 (fr) *	2001-06-12	2002-12-19	Elan Pharmaceuticals, Inc.	Macrocycles utiles dans le traitement de la maladie d'alzheimer
US7439251B2 (en)	2002-05-03	2008-10-21	Israel Institute For Biological Research	Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
HRP20220962T1 (hr)	2016-10-05	2022-10-28	Nsc Therapeutics Gmbh	Kristalni polimorfi agonista muskarinskog acetilkolinskog receptora
US12201619B2 (en)	2018-03-22	2025-01-21	Nsc Therapeutics Gmbh	Compounds and methods for use in the treatment of microglia-mediated disorders

2017
- 2017-10-05 HR HRP20220962TT patent/HRP20220962T1/hr unknown
- 2017-10-05 SG SG11201901612TA patent/SG11201901612TA/en unknown
- 2017-10-05 WO PCT/EP2017/075373 patent/WO2018065529A1/fr not_active Ceased
- 2017-10-05 SI SI201731206T patent/SI3523310T1/sl unknown
- 2017-10-05 PE PE2019000719A patent/PE20191003A1/es unknown
- 2017-10-05 AU AU2017341088A patent/AU2017341088B2/en active Active
- 2017-10-05 DK DK17788131.5T patent/DK3523310T3/da active
- 2017-10-05 KR KR1020197010921A patent/KR102710640B1/ko active Active
- 2017-10-05 PH PH1/2019/550048A patent/PH12019550048B1/en unknown
- 2017-10-05 CN CN201780060800.4A patent/CN109790180A/zh active Pending
- 2017-10-05 MD MDE20190908T patent/MD3523310T2/ro unknown
- 2017-10-05 HU HUE17788131A patent/HUE059720T2/hu unknown
- 2017-10-05 EP EP17788131.5A patent/EP3523310B1/fr active Active
- 2017-10-05 SM SM20220331T patent/SMT202200331T1/it unknown
- 2017-10-05 CA CA3036134A patent/CA3036134A1/fr active Pending
- 2017-10-05 PL PL17788131.5T patent/PL3523310T3/pl unknown
- 2017-10-05 US US16/338,930 patent/US11008342B2/en active Active
- 2017-10-05 MX MX2019003748A patent/MX383581B/es unknown
- 2017-10-05 IL IL265747A patent/IL265747B2/en unknown
- 2017-10-05 RS RS20220724A patent/RS63438B1/sr unknown
- 2017-10-05 PE PE2024002026A patent/PE20250745A1/es unknown
- 2017-10-05 MA MA46464A patent/MA46464B1/fr unknown
- 2017-10-05 PT PT177881315T patent/PT3523310T/pt unknown
- 2017-10-05 ES ES17788131T patent/ES2924432T3/es active Active
- 2017-10-05 EA EA201990376A patent/EA201990376A1/ru unknown
- 2017-10-05 JP JP2019512714A patent/JP7163280B2/ja active Active
- 2017-10-05 LT LTEPPCT/EP2017/075373T patent/LT3523310T/lt unknown
2019
- 2019-02-28 CL CL2019000532A patent/CL2019000532A1/es unknown
- 2019-03-19 ZA ZA2019/01695A patent/ZA201901695B/en unknown
- 2019-03-28 CO CONC2019/0003003A patent/CO2019003003A2/es unknown
2020
- 2020-12-22 US US17/130,564 patent/US11866449B2/en active Active
2022
- 2022-05-18 JP JP2022081233A patent/JP2022119840A/ja active Pending
- 2022-08-04 CY CY20221100533T patent/CY1125464T1/el unknown
2023
- 2023-06-28 IL IL304126A patent/IL304126A/en unknown
- 2023-11-21 US US18/516,585 patent/US20240083914A1/en active Pending
2024
- 2024-01-24 JP JP2024008595A patent/JP2024056724A/ja active Pending

Also Published As

Publication number	Publication date
SI3523310T1 (sl)	2022-10-28
ZA201901695B (en)	2021-08-25
ES2924432T3 (es)	2022-10-06
MD3523310T2 (ro)	2022-10-31
AU2017341088A1 (en)	2019-04-04
LT3523310T (lt)	2022-08-25
BR112019005450A2 (pt)	2019-06-18
CL2019000532A1 (es)	2019-07-12
PT3523310T (pt)	2022-08-04
IL265747A (en)	2019-06-30
PE20191003A1 (es)	2019-07-15
MX2019003748A (es)	2019-08-12
KR20190056398A (ko)	2019-05-24
CO2019003003A2 (es)	2019-04-12
JP2019529389A (ja)	2019-10-17
US20240083914A1 (en)	2024-03-14
IL265747B1 (en)	2023-08-01
KR102710640B1 (ko)	2024-09-27
JP2024056724A (ja)	2024-04-23
JP2022119840A (ja)	2022-08-17
US20200040007A1 (en)	2020-02-06
CA3036134A1 (fr)	2018-04-12
EP3523310B1 (fr)	2022-05-18
RS63438B1 (sr)	2022-08-31
US11008342B2 (en)	2021-05-18
MA46464B1 (fr)	2022-10-31
US20210238195A1 (en)	2021-08-05
CY1125464T1 (el)	2025-05-09
EP3523310A1 (fr)	2019-08-14
AU2017341088B2 (en)	2021-06-24
HUE059720T2 (hu)	2022-12-28
US11866449B2 (en)	2024-01-09
HRP20220962T1 (hr)	2022-10-28
EA201990376A1 (ru)	2019-11-29
SG11201901612TA (en)	2019-03-28
MX383581B (es)	2025-03-14
PE20250745A1 (es)	2025-03-13
IL265747B2 (en)	2023-12-01
NZ751538A (en)	2024-10-25
CN109790180A (zh)	2019-05-21
DK3523310T3 (da)	2022-08-08
PL3523310T3 (pl)	2022-08-29
JP7163280B2 (ja)	2022-10-31
PH12019550048B1 (en)	2023-12-06
WO2018065529A1 (fr)	2018-04-12
IL304126A (en)	2023-09-01
SMT202200331T1 (it)	2022-09-14
PH12019550048A1 (en)	2019-07-24

Publication	Publication Date	Title
IL286923A (en)	2021-10-31	G protein-coupled receptor (gpcr) modulation by imipridones
EP3697759A4 (fr)	2021-05-12	Antagonistes du récepteur muscarinique de l'acétylcholine m4
DK3762380T3 (da)	2022-01-17	Phenylpyrrolidinon-formylpeptid-2-receptoragonister
PL3283110T3 (pl)	2022-06-27	Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
EP3344295A4 (fr)	2019-05-01	Récepteurs d'antigène chimère tn anti-sialyle
EP3488670A4 (fr)	2020-03-18	Technologies d'architecture de bâti
DK3368060T3 (da)	2020-08-24	Glugacon-receptor-agonister
EP3521427A4 (fr)	2020-04-22	Co-récepteur de récepteur odorant
DK3440105T3 (da)	2022-06-13	T-cellereceptorer
DK3440106T3 (da)	2021-10-04	T-cellereceptorer
DK3494133T3 (da)	2022-09-19	Anti-kras-g12d-t-cellereceptorer
EP3430731A4 (fr)	2019-10-09	Architecture d'iugw
MA49639A (fr)	2020-05-27	Polymorphes de 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one
DK3558995T3 (da)	2023-10-02	Polymorfer
DK3558961T3 (da)	2021-04-12	Polymorfer
EP3651762A4 (fr)	2021-02-24	Antagonistes du récepteur muscarinique de l'acétylcholine m4
PT4039675T (pt)	2024-09-16	Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
DK3713928T3 (da)	2022-04-04	Hidtil ukendte bradykinin-b2-receptorantagonister
MA40858A (fr)	2021-03-31	Composés antagonistes des récepteurs d3 à la dopamine
EP3529267C0 (fr)	2023-07-26	Récepteur de lymphocytes t
EP3697781A4 (fr)	2021-06-30	Antagonistes du récepteur muscarinique de l'acétylcholine m4
EP3440051A4 (fr)	2019-11-27	Agonistes du récepteur du neuropeptide s (npsr)
PT3728208T (pt)	2024-12-05	Polimorfos
EP3318577A4 (fr)	2019-01-23	Anticorps agoniste d'antiplexine a1
DK3334721T3 (da)	2021-06-28	Cgrp-receptorantagonister